Pharmaceutical Research

, Volume 16, Issue 6, pp 828–834 | Cite as

Pharmaceutical Dry Powder Aerosols: Correlation of Powder Properties with Dose Delivery and Implications for Pharmacodynamic Effect

  • Neville M. Concessio
  • Michiel M. VanOort
  • Michael R. Knowles
  • Anthony J. Hickey


Purpose. Efficient dispersion of bulk solids is critical for dry powder aerosol production which can be viewed as a sequence of events from stationary through dilated, flowing and finally dispersed particulates. The purpose of this study was to test the hypothesis that numerical descriptors of powder flow properties predict aerosol dispersion and pharmacodynamic effect.

Methods. Drug and excipient particles were prepared in size ranges suitable for inhalation drug delivery, and their physico-chemical properties were evaluated. Novel techniques (chaos analysis of dynamic angle of repose and impact force separation) were developed and utilized to measure and characterize powder flow and particle detachment from solid surfaces, respectively. Dry powder aerosol dispersion was evaluated using inertial impaction. Pharmacodynamic evaluations of bronchodilation were performed in guinea pigs, for selected formulations.

Results. We observed a direct correlation of powder flow with ease of particle separation (r2 = 0.9912) and aerosol dispersion (r2 = 0.9741). In vivo evaluations indicated that formulations exhibiting a higher in vitro dose delivery resulted in a greater reduction in pulmonary inflation pressure.

Conclusions. These results integrate powder behavior at various levels and indicate that numerical descriptors of powder flow accurately predict dry powder aerosol dispersion. A proportionality between aerosol dispersion and pharmacodynamic effect was observed in preliminary in vivo evaluations, which demonstrates the potential of these techniques for correlation studies between in vitro powder properties and in vivo effect.

dry powder aerosols powder flow capacity dimension impact force separation dispersion pharmacodynamic effect bronchodilation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    A. R. Clark. Medical aerosol inhalers: past, present and future. Aerosol Sci. and Tech. 22:374–391 (1995).Google Scholar
  2. 2.
    S. P. Newman and S. W. Clarke. Therapeutic aerosols, 1, physical and practical considerations. Thorax. 38:881–886 (1983).Google Scholar
  3. 3.
    G. Scheuch and W. Stahlhofen. Deposition and dispersion of aerosols in the airways of the human respiratory tract: the effects of particle size. Exp. Lung Res. 18:343–358 (1992).Google Scholar
  4. 4.
    S. P. Newman. In S. W. Clark and D. Pavia (eds), Aerosols and the Lung: Clinical and Experimental Aspects, Butterworths, London, 1984, pp. 197–224.Google Scholar
  5. 5.
    P. J. Davies, G. W. Hanlon, and A. J. Molyneux. An investigation into the deposition of inhalation aerosol particles as a function of air flow rate in a modified Kirk lung. J. Pharm. Pharmacol. 28:908–911 (1976).Google Scholar
  6. 6.
    J. Visser. An invited review: Van der Waals and other cohesive forces affecting powder fluidization. Powder Tech. 58:1–10 (1989).Google Scholar
  7. 7.
    A. J. Hickey, N. M. Concessio, M. M. VanOort, and R. M. Platz. Factors influencing the dispersion of dry powders as aerosols. Pharm. Tech. 18:58–64 (1994).Google Scholar
  8. 8.
    N. M. Concessio. Dynamic properties of pharmaceutical powders and their impact on aerosol dispersion, thesis, University of North Carolina at Chapel Hill (1997).Google Scholar
  9. 9.
    A. J. Hickey and N. M. Concessio. Flow properties of selected pharmaceutical powders from a vibrating spatula. Part. Part. Syst. Charac. 11:457–462 (1994).Google Scholar
  10. 10.
    P. Speiser and R. Tawashi. Misch wirkung Pharmazeutisch ver wendeter Pulvermischer. Pharm. Acta. Helv. 37:529–543 (1962).Google Scholar
  11. 11.
    J. T. Carstensen. Pharmaceutical Principles of Solid Dosage Forms, Technomic Publishing Company, Lancaster, 1993.Google Scholar
  12. 12.
    A. J. Hickey and N. M. Concessio. Chaos in rotating lactose powder beds. Particulate Sci. and Tech. 14:15–25 (1996).Google Scholar
  13. 13.
    N. M. Concessio and A. J. Hickey. Analysis of the patterns of particle dispersion from a dry powder inhaler. Pharm. Tech. 20:50–62 (1996).Google Scholar
  14. 14.
    A. J. Hickey and N. M. Concessio. Descriptors of irregular particle morphology and powder properties. Adv. Drug Del. Rev. 26:29–40 (1997).Google Scholar
  15. 15.
    F. C. Moon. Chaotic and Fractal Dynamics, John Wiley and Sons, New York, 1992.Google Scholar
  16. 16.
    D. Ruelle. Strange attractors. Math Intelligencer 2:126–137 (1980).Google Scholar
  17. 17.
    B. Kaye. Chaos and Complexity: Discovering the Surprising Patterns of Science and Technology, VCH Publishers, New York, 1993, pp. 64–70.Google Scholar
  18. 18.
    H. Froehling, J. P. Crutchfield, D. Farmer, N. H. Packard, and R. Shaw. On determining the dimension of chaotic flows. Physica. 3D:605–617 (1981).Google Scholar
  19. 19.
    J. D. Farmer, E. Ott, and J. A. Yorke. The dimension of chaotic attractors. Physica. 7D:153–180 (1983).Google Scholar
  20. 20.
    A. Otsuka, K. Kida, K. Danjo, and H. Sunada. Measurement of the adhesive force between particles of powdered organic materials and a glass substrate by means of the impact separation method, I, effect of temperature. Chem. Pharm. Bull. 31:4483–4488 (1983).Google Scholar
  21. 21.
    B. A. Webber, J. V. Collins, and M. A. Braithewaite. Sever acute asthma: a comparison of three methods of inhaling Salbutamol. Br. J. Dis. Chest. 76:69–74 (1982).Google Scholar
  22. 22.
    B. S. Cohen. The first 40 years. In J. P. Lodge and T. L. Chan (eds), Cascade Impactor, Sampling and Data Analysis, American Industrial Hygiene Assoc., Ohio, 1986.Google Scholar
  23. 23.
    J. P. Mitchell, P. A. Costa, and S. Waters. An assessment of an Andersen Mark-II cascade impactor. J. Aerosol Sci. 19:231–221 (1988).Google Scholar
  24. 24.
    R. M. Auty, K. Brown, M. Neale, and P. D. Snashall. Respiratory tract deposition of sodium cromoglycate is highly dependent upon technique of inhalation using the Spinhaler. Br. J. Dis. Chest. 81:371–380 (1987).Google Scholar
  25. 25.
    M. VanOort, B. Downey, and W. Roberts. Verification of operating the Andersen cascade impactor at different flow rates. Pharm. Forum. 22:2211–2215 (1996).Google Scholar
  26. 26.
    N. M. Concessio, R. Jager-Waldau, and A. J. Hickey. Aerosol delivery from an active emission multi-single dose dry powder inhaler. Particulate Sci. Tech. 15:51–63 (1997).Google Scholar
  27. 27.
    S. Desquand, J. Lefort, C. Dumarey, and B. B. Vargaftig. The booster injection of antigen during active sensitization of guinea pig modifies the anti-anaphylactic activity of the PAF antagonist WEB 2086. Br. J. Pharmacol. 100:217–222 (1990).Google Scholar
  28. 28.
    D. A. Handley, J. J. DeLeo, and A. M. Havill. Induction of aerosol allergen of sustained and nonspecific IgE-mediated airway hyperactivity in the guinea pig. Agents Actions. 37:201–203 (1992).Google Scholar
  29. 29.
    H. Konzett and R. Roessler. Versuchsanordnung zu untersuchungen an der Bornchialmuskulatur. Naunyn Schmiedeberg. Arch. Exp. Path. Pharmakol. 195:71–74 (1940).Google Scholar
  30. 30.
    J. S. Franzone, R. Cirillo, and P. Biffignandi. Doxofylline exerts a prophylactic effect against bronchoconstriction and pleurisy induced by PAF. Eur. J. Pharmacol. 165:269–277 (1989).Google Scholar

Copyright information

© Plenum Publishing Corporation 1999

Authors and Affiliations

  • Neville M. Concessio
    • 1
    • 2
  • Michiel M. VanOort
    • 3
  • Michael R. Knowles
    • 4
  • Anthony J. Hickey
    • 1
  1. 1.Division of Pharmaceutics, School of PharmacyUniversity of North CarolinaChapel Hill
  2. 2.Pharmaceutical Division, BiotechnologyBayer CorporationBerkeley
  3. 3.Inhalation Product DevelopmentGlaxoWellcome Inc., RTP
  4. 4.Cystic Fibrosis Pulmonary Research and Treatment CenterUniversity of North CarolinaChapel Hill

Personalised recommendations